Treatment with salanersen slowed neurodegeneration and improved motor function in children with SMA in a Phase 1 trial, ...

Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced ...

New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

Nusinersen was generally well tolerated with no new safety concerns identified with eight years of follow-up. All participants had at least one AE, the majority of which were mild to moderate in ...

Living with SMA isn't just about survival, says columnist. There's also the emotional weight of preparing for the next crisis ...

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

Type IV SMA manifests during adulthood, but those diagnosed are generally able to remain active and experience a normal life expectancy. 3 According to the NfL data regarding Spinraza, participants ...

Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with ...

Spinraza (nusinersen) is a brand-name drug that’s prescribed for spinal muscular atrophy (SMA) in adults and children. Spinraza comes as a spinal injection that’s given by a healthcare ...

Biogen Inc BIIB announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA. RESPOND is an ongoing two-year, phase 4 open-label ...

SPINRAZA is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body. 2 It is ...

Spinraza, Zolgensma, and Evrysdi are all used to treat SMA. Spinraza and Evrysdi are used in adults and children of any age, while Zolgensma is used only in children younger than 2 years old.